ANTIARRHYTHMIC EFFECT OF CHRONIC ORAL AMIODARONE TREATMENT IN DOGS WITH MYOCARDIAL-INFARCTION AND REPRODUCIBLY INDUCIBLE SUSTAINED VENTRICULAR ARRHYTHMIAS

The antiarrhythmic effect of an 8-week oral amiodarone regimen was studied in dogs with 1-week-old myocardial infarction and reproducibly inducible sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). Eighteen dogs were randomly assigned to receive either amiodarone, 40 mg/kg/day for 10 days, followed by 30 mg/kg/day for 4 days and then 20 mg/kg/day for 6 weeks (N = 9), or placebo (N = 9). Programmed electrical stimulation was conducted weekly in the two treatment groups. Plasma concentrations of amiodarone and desethylamiodarone were determined weekly, and their myocardial concentrations in the noninfarcted and infarcted regions of the left ventricle were measured at the end of the study. Suppression of inducible arrhythmias was observed at weeks 1, 3-7, and 8 in the amiodarone-treated dogs, whereas no suppression occurred in the placebo-treated group. Plasma amiodarone concentration was maximal at 2.5 ± 1.4 μg/ml at week 2, decreased to 1.9 ± 1.1 μg/ml at week 3, and remained steady thereafter. Plasma desethylamiodarone concentrations were in the range of 0.2 ± 0.1 to 0.4 ± 0.2 μg/ml from weeks 1 through 8. Myocardial amiodarone and desethylamiodarone concentrations in the noninfarcted region of the left ventricle were 34.0 ± 15.8 and 20.8 ± 7.8 pg/g, respectively, at the end of the study. The lack of antiarrhythmic effect of amiodarone at week 2 coincided with the highest plasma amiodarone concentration. The data indicate that this dog model of ventricular arrhythmias is useful for studying the antiarrhythmic action of amiodarone. © 1990 Raven Press, Ltd., New York.